Printer Friendly

COPLEY PHARMACEUTICAL ANNOUNCES THE APPROVAL OF LIDOCAINE HYDROCHLORIDE JELLY 2 PERCENT

 CANTON, Mass., April 30 /PRNewswire/ -- Copley Pharmaceutical, Inc. (NASDAQ: CPLY) announced today the approval of Lidocaine Hydrochloride Jelly, USP 2 Percent, the generic version of Xylocaine(R) (Astra Pharmaceutical Products, Inc.).
 Lidocaine Hydrochloride Jelly, USP Two Percent is used for urological procedures and lubrication of endotracheal tubes.
 This approval will augment the line of products which will further Copley Pharmaceutical's penetration into our Managed Care market, which is directed by Gary Skalski.
 Copley Pharmaceutical, Inc. develops, manufactures and markets a broad range of off-patent prescription and over-the-counter pharmaceutical products in a variety of dosage forms and strengths, including extended-release products. The company markets its products to distributors, retail chains, wholesalers, hospitals, government agencies and managed care entities.
 -0- 4/30/93
 /CONTACT: Dr. Mark Hirsh, executive vice-president-marketing and business development, 800-325-6111 or 617-821-6111/
 (CPLY)


CO: Copley Pharmaceutical, Inc. ST: Massachusetts IN: MTC SU: PDT

DJ -- NE004 -- 3099 04/30/93 10:02 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 30, 1993
Words:153
Previous Article:CABOT ANNOUNCES SECOND QUARTER OPERATING RESULTS
Next Article:COSTAR CORPORATION ANNOUNCES RESULTS FOR FIRST QUARTER 1993
Topics:


Related Articles
PERRIGO TO MARKET MICONAZOLE CREAM VIA A JOINT PRODUCT AGREEMENT WITH COPLEY PHARMACEUTICAL, INC.
COPLEY PHARMACEUTICAL ANNOUNCES THE APPROVAL OF FLUPHENAZINE HYDROCHLORIDE ELIXIR USP
COPLEY PHARMACEUTICAL ANNOUNCES THE APPROVAL OF METHAZOLAMIDE TABLETS USP, 25 & 50 MG
COPLEY PHARMACEUTICAL, INC. RECEIVES FDA APPROVAL FOR MEBENDAZOLE CHEWABLE TABLETS, 100 MG
COPLEY PHARMACEUTICAL, INC. BEGINS SHIPPING TWO NEW PRODUCTS
COPLEY PHARMACEUTICAL ANNOUNCES AVAILABILITY OF HYDROXYCHLOROQUINE TABLETS AND APPROVAL OF CAPTOPRIL TABLETS
IVAX CORPORATION ANNOUNCES U.K. GENERIC DRUG APPROVAL
FIRST GENERIC DRUG FOR PINWORM RELEASED FOR U.S. MARKET, COPLEY PHARMACEUTICAL ANNOUNCES
FIRST ALTERNATIVE FOR CORTENEMA RELEASED FOR U.S. MARKET
FDA Approves Copley Pharmaceutical's ANDA for Procainamide HCl 1000 mg Tablets

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters